The Antidote: Inside the World of New Pharma (83 page)

Kwong’s departure from,
39
–40,
42
,
44

Merck’s acquisition of,
199
–200,
217
–18,
245
,
260
,
311

Merck’s AdComm presentation and,
230
,
265
–66

Schmidt, Benno, Sr.,
64
,
143
–44

Schoenebaum, Mark,
317
,
342
,
365
,
368
,
381

Science
,
54
,
320
–21

Scolnick, Edward,
14
–15,
31
,
94
,
121

Searle,
19
,
30
,
32
,
35
–36,
60

Sears,
148
,
162

Securities and Exchange Commission (SEC),
74
–75,
149
,
175
,
369
–71

Shareholders Foundation,
369

Shire PLC,
123
,
184
,
188
,
210
,
260
,
310
,
357

Silva, Paul,
370

Singhal, Priya,
256
–58,
268

Smith, Ian,
106
,
111
,
114
,
197
,
199
,
211
–12,
214
,
222
,
238
,
247
,
280
–83,
287
–88,
322
–25,
368
,
375
,
383

Boger’s relationship with,
86
–87,
163
,
280
–81,
325

CF and,
248
,
281
,
295
–98,
300
,
302
,
304
,
313
,
325
,
345
,
350

earnings calls and,
175
,
177
–78,
308
–9,
324
–25,
339
–41,
362

Emmens’s relationship with,
314
–15,
325

financial problems and,
87
–88,
98
–99,
186

financial tutorial of,
281
–83

HCV and,
130
–32,
137
,
149
–51,
178
,
262
,
324
–25,
347
–50,
376

hiring of,
73
–74

Incivek and,
177
,
186
–87,
212
,
264
,
281
–83,
285
–86,
303
,
308
,
313
–14,
325
,
328
,
330
,
332
,
340
–42,
362

investor day and,
101
–2

Liver Meeting and,
212
,
324

nucs and,
314
,
325
,
347

sodium channels,
126
–27

Spitzer, Eliot,
96

Stamoulis, Christiana,
380
–81

Star Trek
,
29
,
155

statins,
6
,
14
–15,
98

stem cell research,
70
,
204
–5,
322

Stevens-Johnson syndrome (SJS),
257
,
272
,
343

Stewart, Martha,
216
,
369

stock market,
11
–12,
58
–59

Emmens on,
261
,
310

and grand contradiction in pharmaceutical industry,
246
–47

Merck and,
265
,
311

and mergers and acquisitions,
84
–85,
199
–200

9/11 and,
73

Pfizer and,
245
–46

Pharmasset and,
197
,
262
,
329
,
349

Vertex and,
59
,
73
,
75
,
77
,
87
,
96
–97,
99
,
101
,
102
,
146
,
148
,
178
,
185
–86,
212
–13,
247
,
283
,
311
–14,
315
,
324
–25,
329
–33,
339
–42,
343
–46,
351
–56,
357
,
364
–65,
367
–71,
378
,
382

structure-based drugs, structure-based design,
11
,
14
,
16
–17,
19
,
30
,
40
,
66
,
75
,
88
,
113

HCV and,
34
,
39

kinases and,
54
–56

Su, Michael,
53
–54

sulfonamides,
31
–32,
35

Supreme Court, U.S.,
6
,
59
,
372

sustained viral response (SVR) rates:

HCV and,
105
,
132
,
220
,
266
,
333
,
348
,
351
,
359

of Incivek,
151
,
171
,
212
,
274
–75,
282

sweat chloride,
79
,
179
–80,
296
–97,
302
,
304
,
344
,
364

Syntex Laboratories,
128
,
227

systems biology,
206
–7

target-based drugs,
87
–88,
106
,
322

telaprevir,
see
Incivek

tenofovir,
225

Tenth International Conference on Antiviral Research,
39

TheStreet,
311
,
358

Third International Conference on the Prevention of Infection,
31
–32

Thomson, John,
45
,
65
,
71
,
97
,
113
,
116
,
158
,
385

active protein research and,
16
–18

Boger’s vision and,
291
,
335

China and,
169
–70,
173
,
290
–91,
326

HCV and,
21
,
23
,
33
–34,
37
,
39
,
41
,
63
–64,
78
,
83
,
94
,
169
–70,
232
,
290
–91,
326

HIV and,
18
,
28

Kwong’s recruitment and,
39
–41

layoffs and,
88
–90

management style and skills of,
78
,
89
–90

Vertex’s collaborations managed by,
144
–45

Thomson Units,
17
,
35

Tibotec Pharmaceuticals,
207
–8,
223
,
227
,
231
,
265
,
277

Time
,
96
–97,
152

Timmerman, Luke,
199
,
220
–21,
318
,
360
,
363

Tinmouth, Phil,
141
–42

Tishler, Max,
152

transplants,
128
,
177

CF and,
67
,
125
,
252

HCV and,
63
,
139
,
151
,
256

Tsien, Roger,
66
–67

tuberculosis (TB),
145

China and,
170
,
173
–74

and side effects of Incivek,
269
–70

Tung, Roger,
65
,
78
,
117
–19,
126
,
144

CF and,
81
,
118

HCV and,
39
,
48
–49,
63
–64,
232

HIV and,
19
,
25
–26,
28
,
30
–31,
91

Kwong’s recruitment and,
39
–41

Washington retroviral conference and,
25
–26,
30

Tyler, Steven,
320

United Kingdom,
73
,
76
,
86
,
97
,
123
,
239
,
334
,
377

vaccines,
3
,
20
,
22
,
97
,
183

Vagelos, Roy,
5
,
15
,
115
,
163

valuation,
see
stock market

value, of drugs, economic,
52
,
69
,
84
,
93
,
97
,
111
,
120
,
145
,
178
,
196
,
212
–13,
245
,
298
,
313
,
317
,
341
–42,
363
,
377

Emmens on,
217
,
261
,
330
,
332
,
341

value, of drugs, to patients and society,
15
,
43
,
84
,
131
,
194
,
202
,
280
,
288
,
322
,
325
,
376
,
388

pricing and,
286
,
288

shareholder value vs.,
127
,
246
,
261
,
332

values and culture, company,
45
,
116
–17

of Merck,
162
,
245
–46

of Vertex,
49
,
116
–17,
127
,
133
–35,
157
–62,
203
–4,
205
,
226
,
277
,
280
,
358
,
376
,
387

Vancouver AIDS conference,
36
,
230

Van Goor, Fred,
118
–21,
125
,
127
,
141
–43,
300
,
337
,
344
,
371

Vasella, Daniel,
56
–58

VCH-222,
see
VX-222

Vertex Pharmaceuticals:

acquisitions by,
66
–69,
73
,
75
,
78
–81,
84
–86,
127
,
197
,
199
–200,
220
,
287
–88,
299
,
354
,
385

alleged federal violations of,
369
–71

business plan and model of,
194
,
204
,
217
,
259
–60,
316
–17

China and,
169
–70,
173
–74,
291
,
327

commercialization of,
51
,
196
–98,
207
,
209
–11,
217
–19,
221
–22,
277

corporate and scientific culture of,
18
,
39
–42,
116
–17,
133
,
135
,
159
,
161
–62,
198
,
205
,
211
,
219
,
282
,
290
–91,
293
–94,
323
,
333
,
335
,
337
–38,
354
,
356
,
361
,
368
,
374
,
376
,
380
,
386

creativity of,
57
,
70
,
161
–62,
260
,
281
,
333
,
385
,
387

credibility of,
56
,
332
,
365

disclosure meetings of,
130
–31,
247
–49,
295

disorganization of,
27

employee turnover at,
184
–85,
200
,
241
,
334
–38,
370
,
379
,
386

externalities of,
157

as feared and fearless,
110

finances of,
1
–2,
7
,
11
–14,
23
,
26
–27,
36
,
40
–44,
46
–47,
49
–52,
56
,
58
–60,
65
–66,
68
,
73
–75,
77
,
82
–88,
90
,
96
–99,
101
–2,
106
,
108
–11,
114
,
127
,
129
–31,
137
,
139
–42,
145
–46,
149
,
158
,
162
,
168
,
171
–72,
175
–78,
185
–87,
189
,
191
,
194
,
198
–99,
207
,
211
–12,
217
,
222
–23,
225
,
237
–38,
240
,
245
–47,
249
–50,
259
,
262
,
276
,
280
–83,
287
,
290
–91,
297
–301,
307
–15,
318
,
324
–25,
327
–33,
339
–47,
350
–65,
368
–70,
372
,
376
,
378
,
380
–82,
386
,
388